Beneficial Effect of Growth Hormone Treatment on Health-Related Quality of Life in Children with Prader-Willi Syndrome: A Randomized Controlled Trial and Longitudinal Study.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The researchers, therefore, investigated the effects of GH treatment on HRQOL in PWS children.

Who Took Part

The study group was 26 children.

By PubMed's age tags, the people studied were children and teenagers, both men and women.

In a randomized controlled GH trial including 26 PWS children and during an 11-year longitudinal GH study in 76 children, the researchers annually assessed HRQOL recorded by patients and parents, using a generic questionnaire (DUX25), containing 4 subdomains (Physical, Home, Social, and Emotional) and a PWS-specific questionnaire (DUXPW).

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

What Was Measured

PubMed files the paper under topics including Body Composition, Health Status, Hormone Replacement Therapy, Human Growth Hormone, Longitudinal Studies, Prader-Willi Syndrome and Quality of Life.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 26 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Hormone research in paediatrics), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.